Ranbaxy Laboratories Jumps as US Plant Wins FDA Clearance

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In a rare bit of good news for Ranbaxy Laboratories, the generic drugmaker says its Ohm Laboratories facility in New Jersey successfully passed an FDA inspection. The move is significant because the plant is the only Ranbaxy manufacturing facility that is permitted to supply products to the US market after three plants in India were prevented from doing so thanks to serious quality-control issues. The FDA endorsement means that Ranbaxy can use the Ohm facility to file for FDA approvals for drugs, such as a generic version of the widely used Diovan heart drug sold by Novartis (NVS).

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC